The goal of this project is to develop biologics that direct release of target protein extracellular domains from the membrane.  As this strategy is general, it has the potential for broad impact as a method to shed a pathologic protein ectodomain and silence its activity. The long-term development plan is to extend this technology to silence the functions of a broad range of target proteins.

Funding

Funding Duration

January 12, 2026 - January 11, 2027

Funding level

Emergency

People

Principal Investigator

Stephen Blacklow

MD, PhD
Gustavus Adolphus Pfeiffer Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School
Collaborators